OncoSec Medical Inc

OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we are working to deliver safe and effective cancer treatments that can provide long-term benefits for patients. Our core technology platform continues to advance through clinical trials for various cancers. Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer. We have a track record of establishing, operating and evolving high-performance partnerships globally.

Every year, there are over 18 million cases of cancer detected and 10 million cancer related deaths. In fact, it is estimated that there are 1.6 million new cases of solid tumors in the U.S. alone – presenting one of the largest challenges to oncologists.

Certain cancers can bypass or hide from the immune system by engaging an immune checkpoint called PD-1, which represents an “off-switch” that cancers can exploit to escape from cancer-fighting T-cells. New treatments, called checkpoint inhibitors, block these “off-switches” and help keep cancer-fighting T-cells in attack mode to eliminate tumor cells.

However, anti-PD-1 checkpoint inhibitors that work to turn off the “off-switches” are only effective in an estimated 30% of the patients that receive these drugs. The other 70% of patients who receive anti-PD-1 checkpoint inhibitors don’t see their tumors go away. Those tumors lack essential immune elements that enable anti-PD-1 checkpoint therapy benefits. They are known as “cold” tumors – while “hot” tumors are more likely to receive a benefit from checkpoint inhibitors. Our lead product candidate, TAVO™ (tavokinogene telseplasmid) is designed to help turn “cold” tumors “hot.”